1365. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results From Asia-Pacific (APAC) and Latin America (LA)

BACKGROUND: LEF, a novel pleuromutilin antibiotic for IV and oral use, recently completed a phase 3 trial for the treatment of CABP in adults where it demonstrated noninferiority to moxifloxacin ± linezolid. LEF selectively inhibits bacterial translation. This study investigated the activity of LEF...

Descripción completa

Detalles Bibliográficos
Autores principales: Paukner, Susanne, Flamm, Robert K, Gelone, Steven P, Sader, Helio S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252924/
http://dx.doi.org/10.1093/ofid/ofy210.1196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252924/
http://dx.doi.org/10.1093/ofid/ofy210.1196

Ejemplares similares